Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Serabelisib - Takeda Oncology

Drug Profile

Serabelisib - Takeda Oncology

Alternative Names: INK-1117; MLN-1117; PETRA-06; TAK-117

Latest Information Update: 17 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellikine
  • Developer Avera Cancer Institute; Baylor Research Institute; European Network for Translational Research in Ovarian Cancer (EUTROC); Takeda; Takeda Oncology
  • Class Antineoplastics; Imidazoles; Morpholines; Pyridines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Endometrial cancer; Renal cell carcinoma
  • Phase I Solid tumours
  • Discontinued Gastric cancer; Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 25 Mar 2019 Petra Pharma and Takeda Pharmaceutical entered a license agreement to develop, manufacture and commercialise serabelisib for solid tumours
  • 20 Mar 2019 Petra plans a phase Ib/II trial for Solid tumors (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in November 2019 (NCT04073680)
  • 28 Oct 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top